ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Search Committee Finishes Job, Submits Choices To Califano

April 15, 1977

Wallen Pleads Guilty To Lesser Charges, To Pay $20,000 to CALGB, FDA

August 31, 1984

FA Drug Approval on Activity, Rather Than Survival Urged By NCU

January 13, 1989

Nancy Brinker Resigns As CEO of Komen

August 10, 2012

In Brief: Columbia Still In Running As Comprehensive Center In ’78; Illinois Withdraws Application

June 24, 1977

In Brief NCI-FDA Relations Tops, DeVita Says; Upon Talks to Candidates For Prospective Division

November 24, 1978